Filing Details
- Accession Number:
- 0001209191-18-051472
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-09-18 16:28:03
- Reporting Period:
- 2018-09-17
- Accepted Time:
- 2018-09-18 16:28:03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1326732 | Xencor Inc | XNCR | Pharmaceutical Preparations (2834) | 201622502 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1591213 | A Paul Foster | C/O Xencor, Inc. 111 West Lemon Avenue Monrovia CA 91016 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-09-17 | 40,000 | $11.05 | 44,952 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-09-17 | 40,000 | $46.03 | 4,952 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2018-09-17 | 40,000 | $0.00 | 40,000 | $11.05 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 10,000 | 2024-02-20 | No | 4 | M | Direct |
Footnotes
- Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted August 17, 2018.
- The weighted average sale price for the transaction reported was $46.0302, and the range of prices were between $46.0121 and $46.0782. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
- The stock option is fully vested.
Billionaire Hedge Funds
